Purpose: This article aims to evaluate how the subfoveal choroidal thickness (SFCT) and bestcorrected visual acuity (BCVA) respond to the intravitreal injection of bevacizumab and to assess the correlation between these changes. It will also assess the use of the baseline SFCT as a predictor for BCVA changes in eyes of treatment-naive, diabetic macular edema (DME) patients. Methods: This retrospective, consecutive case series comprised 59 eyes of 39 treatmentnaive DME patients. Complete slit-lamp assessment, swept-source optical coherence tomography (SS-OCT) scans to measure SFCT and BCVA values were performed at two stages: baseline and one month after the third monthly injection of intravitreal bevacizumab. Results: Patients' ages ranged from 46.3 to 76.4 years (mean: 62.6 ± 2.3). The mean SFCT was 318 ± 82 μm at baseline, which decreased after 3 months to 300 ± 66 μm (P-value = 0.021). There was an improvement in the mean of the logMAR best-corrected visual acuity (BCVA) from 0.7 (decimal equivalent: 0.2) to 0.5 (decimal equivalent: 0.3) (P-value = 0.019). There was no association between SFCT changes and BCVA changes (P-value = 0.180). Wilcoxon signed-rank test disclosed that a better BCVA improvement was related to a greater subfoveal choroidal thickness at baseline P-value <0.00. Conclusion: Eyes with a higher baseline subfoveal choroidal thickness (SFCT) attained greater BCVA improvement than eyes with a lower baseline SFCT. In addition to this, changes to SFCT do not appear to correlate with BCVA changes. These findings do not support using OCT SFCT changes as a prognostic factor for changes to BCVA after intravitreal bevacizumab treatment in evaluating treatment-naive DME eyes.

Introduction La persistance de symptômes des mois après l’infection au SARS-CoV-2 et leur diversité sont reconnues par l’Organisation mondiale de la santé, qui déclarait en septembre 2020 : « La COVID-19 peut entraîner une maladie prolongée et des symptômes persistants, y compris chez les jeunes adultes et chez les personnes qui n’ont pas ou peu d’antécédents de santé chroniques et qui n’ont pas été hospitalisées ». Objectif Déterminer les effets à long termes de l’infection COVID-19 3 mois après une atteinte aiguë. Méthodes Étude prospective menée au service de pneumologie de l’hôpital Farhat Hached – Sousse et incluant les patients aux antécédents d’infection COVID-19 depuis 3 mois. Résultats Quarante patients ont consulté dans les 3 mois qui suivent l’atteinte COVID ; 23 étaient des hommes et 17 étaient des femmes. Soixante-dix pour cent ont rapporté la persistance des anomalies cliniques. Les symptômes les plus rapportés étaient, la fatigue (63 %), les céphalées (48 %), les troubles neurocognitifs (38 %), une toux sèche (24 %), la dyspnée d’effort (21 %), des douleurs thoraciques (18 %), un trouble de sommeil (15 %) et une anxiété (12 %). La majorité des patients ont déclaré que cette symptomatologie persistante était similaire à celle vécue au cours de la phase aiguë de la maladie (92 %). On a remarqué que ces plaintes fonctionnelles étaient majoritairement décrites par les femmes (78 % versus 43 % ; p = 0,001). Conclusion D’autres études s’avèrent nécessaires afin d’établir des définitions claires et précises de l’évolution à long terme de cette maladie ; permettant ainsi de poser une stratégie de prise charge précoce et multidisciplinaire.

PurposeOcular manifestations were reported in many recent observations that studied either the effect of COVID-19 directly on eyes or of face mask use. Hence, this study aimed to investigate the effect of COVID-19 on the eyes and make a clear comparison of its direct and indirect effect from face mask-wearing.MethodsThis was a cross-sectional study of both written and web-based questionnaires, distributed among a group of COVID-19 patients and a matched control group, the questionnaire consisted of common demographic data, COVID-19 infection history and its symptoms, focusing on ocular symptoms and the presence of conditions related to or cause eye symptoms. As well as the use of face masks that were assessed in terms of the complained ocular manifestationResultsOf 618 participants, 252 had COVID-19 and 366 never had COVID-19. Ocular manifestation among COVID-19 incidence was 44%, significantly higher than non-infected participants’ incidence (35.8%), adjusted odds ratio, 95% confidence interval (AOR, 95%CI); 1.45 (1.02-2.06)). Eye discharges (p-value = 0.033) and photosensitivity (p-value = 0.003) were noted more commonly among COVID-19 participants compared to healthy control. When comparing long periods of face mask use with each ocular symptom; dry eye based on OSDI, forging body sensation, eye pain and eye discharges, were found significantly common among extended periods of face mask use.ConclusionCOVID-19 pandemic affected eyes, both directly from the virus or from its preventive measure of face mask use.